Hematology

In a phase III trial, momelotinib reduced anemia, constitutional symptoms, and splenomegaly

Consider surgery for primary prevention in people with obesity, researchers suggest

News, features, and commentary about cancer-related issues

Motixafortide plus filgrastim increased adequate harvest rate from 9.5% to 67.5%

Best outcomes with transplantation, but non-transplant patients also benefited from quizartinib

Response rate exceeds 60%, with 15- to 20-month duration with epcoritamab

One of 40 patients changed treatment but all remained on brentuximab regardless of scan results

Increased risk for non-melanoma skin cancer, MDS, AML versus the general population

Molecular or cytogenetic response at 3 months correlated with better survival

Newer therapies and strategies might show more promise for boosting survival

News, features, and commentary about cancer-related issues

Treatment with "pediatric-inspired protocols" improved event-free, relapse-free survival

Omicron wave was especially deadly, and those with blood cancers at increased risk

News, features, and commentary about cancer-related issues